Project description
Cancer-responsive therapeutics
Despite advances in treatments, there is no cure for cancer yet. Standard chemotherapy has limited efficacy, and systemic administration of the drugs have significant side effects for healthy tissues. Therefore, more targeted approaches are needed to deliver cancer therapeutics to the tumour site. Funded by the Marie Skłodowska-Curie Actions programme, the GateMOF project aims to develop advanced nanosystems capable of specific drug delivery. These molecular organic frameworks will be biocompatible, overcoming toxicity issues. Their main advantage will be their ability to respond to stimuli from the tumour microenvironment to release the anticancer drugs.
Objective
Cancer is a major societal challenge, as reflected by Horizon's Europe mission on cancer and Europe's Beating Cancer Plan. In particular, despite great advances in cancer treatment in recent decades, its treatment still remains a challenge without an effective cure. In 2020 the EU reported around 3 million new cancer cases and more than 1.2 million deaths, and its incidence is expected to increase in Europe due to its aging population. The standard treatment relies on the systemic administration of chemotherapeutics, which has limited efficacy and causes side effects. To overcome current limitations, GateMOF will develop low-toxicity Molecular Organic Frameworks (MOFs) as advanced nanosystems to tackle cancer. Such Eco-MOFs will be equipped with molecular gates and loaded with anticancer drugs resulting in advanced biocompatible nanosystems with the ability to respond to stimuli present in the tumor intracellular/microenvironment for a selective anticancer drug delivery. The project combines the unique expertise of the host laboratory (Supramolecular Chemistry and Biotechnology) and the candidate (MOF design and synthesis) to ensure the fulfillment of objectives. The fellow will be trained in advanced nanomaterial preparation with molecular gates to obtain stimuli-responsive MOFs for anti-cancer drug delivery, including training for biological studies for their evaluation in vitro in cells and in vivo in animal models. Notably, the project will also allow the fellow to gain experience in patenting and tech transfer. Altogether, GateMOF will develop a new therapeutic technology and provide the fellow with complementary scientific and transferable skills with a significant impact toward an independent research career.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-MSCA-2023-PF-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
46022 Valencia
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.